Abstract:BACKGROUND & OBJECTIVE:The manifestations of old acute myelogenous (AML) patients have their special biological and clinical characteristics, with lower response rate to therapy and shorter survival time. This study was to investigate the prognostic factors of elderly patients with AML retrospectively. METHODS:77 patients aged> or =60 years with AML from 1994 to 2005 were admitted to our study and all the possible prognostic factors were analyzed with Kaplan-Meier survival analysis. The significant factors were further analyzed by Cox proportional hazard model analysis. RESULTS:Seventy-two patients were evaluated. The patients aged 60-70 (median survival time was 350 days) had significantly longer survival time than those aged more than 70 (median survival time is 60 days)(P<0.001), which their CR ratios were 71.4% and 29.4% (P=0.001). The patients with performance status 0 or 1 (median survival time was 402 days) had significantly longer survival time than those with performance status 2, 3 or 4 (median survival time was 31 days)(P<0.001), which their CR ratios were 75% and 15% (P<0.001). The patients with primary AML (median survival time was 98 days) had significantly longer survival time than those with secondary AML (median survival time was 32 days)(P=0.007), which their CR ratios were 50% and 0% (P=0.023). The patients treated with sub-standard dosage of anthracycline (median survival time was 293 days) had significantly longer survival time than those treated with reduced dosage of anthracycline (median survival time was 35 days)(P=0.006), which their CR ratios were 63.6% and 33.3% (P=0.02). The patients with bone marrow blast cell ratio< or =50% (median survival time was 98 days ) had significantly longer survival time than those with bone marrow blast cell ratio >50% (median survival time was 55 days)(P=0.006). The patients with favorable karyotype (median survival time was 293 days) had significantly longer survival time than those with unfavorable or normal karyotype (median survival time was 31 days)(P=0.005). The patients without CD34 expression (median survival time was 201 days) had significantly longer survival time than those with CD34 expression(median survival time was 36 days)(P<0.001). The patients with the peripheral blood white blood cell count (PBWBC)>10x10(9)/L (50%) had significantly higher CR ratio than those with PBWBC< or =10x10(9)/L (25%)(P=0.043). The patients received chemotherapy (50%) had significantly higher CR ratio than those received supportive therapy (0%)(P=0.001). In the stepwise COX proportional hazard regression model, all the seven factors related to OS remained independent and significant. CONCLUSIONS:Factors, including age >70, PS 2 to 4, percentage of blasts in bone marrow >50%, secondary AML, unfavorable karyotype, expression of CD34, lower dosage.

Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia]

Factors Affecting Early Death and Survival of Patients with Acute Promyelocytic Leukemia Treated with ATRA-Based Therapy Regimens

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Analysis of Clinical Characteristics and Prognostic Factors in Elderly Patients with Acute Myeloid Leukemia

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Aging and Comprehensive Molecular Profiling in Acute Myeloid Leukemia.

[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].

Efficacy of different remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia

Analysis of Characteristics and Clinical Effectiveness of Acute Myeloid Leukemia in the Elderly

[Analysis of Factors Influencing Overall Survival and Prognosis of AML Patients Over 50 Years Old]

[Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia].

Acute leukemia in the elderly:clinical analysis of 340 cases

Treatment Patterns and a Prognostic Scoring System for Elderly Acute Myeloid Leukemia Patients: a Retrospective Multicenter Cohort Study in China

Clinical Features and Prognosis of Elderly Patients with Cytogenetically Normal Acute Myeloid Leukemia

Cia_a_343598 55..64

Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen

Clinical and prognostic features of acute promyelocytic leukemia in the elderly

A single center cross-sectional study on the efficacy of low-dose cytarabine and aclramycin combined with granulocyte colony-stimulating factor (CAG regimen) in elder adults with acute myeloid leukemia

[Clinical Characteristics and Efficacy Analysis for Patients over 55 Years of Age with Acute Lymphoblastic Leukemia].

Individual Treatment of Acute Myelogenous Leukemia in Elderly Patients

Cytogenetic Risk and Hemocyte Account for the Age-Related Poor Prognosis in Adult Acute Myeloid Leukemia Patients